FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952264931> ?p ?o ?g. }

• W2952264931 abstract "Background Rheumatoid Arthritis (RA) patients with established disease can have autoantibodies reactive to a broad array of citrullinated antigens. Autoantibodies reactive against several citrullinated proteins can develop 10-15 years before the clinical onset of disease. Objectives We aimed to identify common patterns of citrullinated peptide reactivities that emerge among subjects during progression from a pre-disease state through diagnosis of RA. Methods 500 subjects with RA (based on ICD9-CM code) were identified from the Defense Medical Surveillance System. For each subject, up to four serum samples were obtained from the Department of Defense (DoD) serum repository: 1 from earliest time point before diagnosis (9.2 ± 2.0 years before, mean ± SD); one proximal to (immediately prior to or after) disease diagnosis (127 ± 125 days before diagnosis); plus 2 intermediate time points. A discovery subset of serum samples from 88 RA subjects confirmed to be positive for anti-citrullinated protein antibodies (ACPA) at the diagnosis-proximal time point (>5 U/mL for cyclic citrullinated peptide (CCP)-II test) was assessed for IgG antibodies to 36 antigens (24 citrullinated-peptide antigens among 14 proteins and 12 non-citrullinated antigens among 9 proteins) using a custom Luminex-based assay. Subjects testing above the upper limit of detection for the CCP-II test (300 U/mL) were considered ACPA-high (n=28), with the remainder considered moderate (n=60). Results For the group of ACPA-high subjects at the diagnosis-proximal time point, average IgG autoantibody binding to 9 citrullinated peptide antigens (from 7 proteins: clusterin, enolase, fibrinogen A, fibrinogen B, fibronectin, filaggrin, vimentin) showed significant increases from the earliest through diagnosis-proximal time points at the population level (FDR Conclusion Novel patterns of citrullinated peptide autoantibody reactivities that begin to emerge on average about 6 years before diagnosis of RA have been identified in samples from the US DoD serum repository. Evaluation of specific anti-citrullinated peptide autoantibodies could potentially provide sensitive, patient-tailored biomarkers to monitor disease trajectories as at-risk individuals progress to clinically-defined RA. Disclosure of Interests:  Matthew J Loza Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Sunil Nagpal Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Renee Laird: None declared, Suzanne Cole Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Frederic Baribaud Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Ian Anderson Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Navin Rao Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Mark Riddle: None declared, Chad Porter: None declared" @default.
• W2952264931 created "2019-06-27" @default.
• W2952264931 creator A5011821238 @default.
• W2952264931 creator A5013446926 @default.
• W2952264931 creator A5038818490 @default.
• W2952264931 creator A5042939950 @default.
• W2952264931 creator A5063183571 @default.
• W2952264931 creator A5064055707 @default.
• W2952264931 creator A5070514995 @default.
• W2952264931 creator A5077203387 @default.
• W2952264931 creator A5091761903 @default.
• W2952264931 date "2019-06-01" @default.
• W2952264931 modified "2023-09-25" @default.
• W2952264931 title "OP0118 DISCRETE PATTERNS OF CITRULLINATED PEPTIDE AUTOANTIBODY REACTIVITIES EMERGE DURING PROGRESSION FROM PRE-DISEASE STATE TO DIAGNOSIS OF RHEUMATOID ARTHRITIS" @default.
• W2952264931 doi "https://doi.org/10.1136/annrheumdis-2019-eular.3399" @default.
• W2952264931 hasPublicationYear "2019" @default.
• W2952264931 type Work @default.
• W2952264931 sameAs 2952264931 @default.
• W2952264931 citedByCount "0" @default.
• W2952264931 crossrefType "proceedings-article" @default.
• W2952264931 hasAuthorship W2952264931A5011821238 @default.
• W2952264931 hasAuthorship W2952264931A5013446926 @default.
• W2952264931 hasAuthorship W2952264931A5038818490 @default.
• W2952264931 hasAuthorship W2952264931A5042939950 @default.
• W2952264931 hasAuthorship W2952264931A5063183571 @default.
• W2952264931 hasAuthorship W2952264931A5064055707 @default.
• W2952264931 hasAuthorship W2952264931A5070514995 @default.
• W2952264931 hasAuthorship W2952264931A5077203387 @default.
• W2952264931 hasAuthorship W2952264931A5091761903 @default.
• W2952264931 hasBestOaLocation W29522649311 @default.
• W2952264931 hasConcept C126322002 @default.
• W2952264931 hasConcept C147483822 @default.
• W2952264931 hasConcept C159654299 @default.
• W2952264931 hasConcept C163764329 @default.
• W2952264931 hasConcept C190283241 @default.
• W2952264931 hasConcept C203014093 @default.
• W2952264931 hasConcept C2776232647 @default.
• W2952264931 hasConcept C2777077863 @default.
• W2952264931 hasConcept C2777468819 @default.
• W2952264931 hasConcept C2777575956 @default.
• W2952264931 hasConcept C2779129087 @default.
• W2952264931 hasConcept C2779476363 @default.
• W2952264931 hasConcept C48632299 @default.
• W2952264931 hasConcept C515207424 @default.
• W2952264931 hasConcept C55493867 @default.
• W2952264931 hasConcept C71924100 @default.
• W2952264931 hasConcept C86803240 @default.
• W2952264931 hasConceptScore W2952264931C126322002 @default.
• W2952264931 hasConceptScore W2952264931C147483822 @default.
• W2952264931 hasConceptScore W2952264931C159654299 @default.
• W2952264931 hasConceptScore W2952264931C163764329 @default.
• W2952264931 hasConceptScore W2952264931C190283241 @default.
• W2952264931 hasConceptScore W2952264931C203014093 @default.
• W2952264931 hasConceptScore W2952264931C2776232647 @default.
• W2952264931 hasConceptScore W2952264931C2777077863 @default.
• W2952264931 hasConceptScore W2952264931C2777468819 @default.
• W2952264931 hasConceptScore W2952264931C2777575956 @default.
• W2952264931 hasConceptScore W2952264931C2779129087 @default.
• W2952264931 hasConceptScore W2952264931C2779476363 @default.
• W2952264931 hasConceptScore W2952264931C48632299 @default.
• W2952264931 hasConceptScore W2952264931C515207424 @default.
• W2952264931 hasConceptScore W2952264931C55493867 @default.
• W2952264931 hasConceptScore W2952264931C71924100 @default.
• W2952264931 hasConceptScore W2952264931C86803240 @default.
• W2952264931 hasLocation W29522649311 @default.
• W2952264931 hasOpenAccess W2952264931 @default.
• W2952264931 hasPrimaryLocation W29522649311 @default.
• W2952264931 hasRelatedWork W125531543 @default.
• W2952264931 hasRelatedWork W2008898877 @default.
• W2952264931 hasRelatedWork W2064349379 @default.
• W2952264931 hasRelatedWork W2085515874 @default.
• W2952264931 hasRelatedWork W2107581946 @default.
• W2952264931 hasRelatedWork W2157799721 @default.
• W2952264931 hasRelatedWork W2332781556 @default.
• W2952264931 hasRelatedWork W2334859570 @default.
• W2952264931 hasRelatedWork W2335367048 @default.
• W2952264931 hasRelatedWork W2350394441 @default.
• W2952264931 hasRelatedWork W2415513304 @default.
• W2952264931 hasRelatedWork W2552976477 @default.
• W2952264931 hasRelatedWork W2754105668 @default.
• W2952264931 hasRelatedWork W2755080112 @default.
• W2952264931 hasRelatedWork W2906216983 @default.
• W2952264931 hasRelatedWork W2951189825 @default.
• W2952264931 hasRelatedWork W2970697665 @default.
• W2952264931 hasRelatedWork W2991656622 @default.
• W2952264931 hasRelatedWork W3040028641 @default.
• W2952264931 hasRelatedWork W3164994448 @default.
• W2952264931 isParatext "false" @default.
• W2952264931 isRetracted "false" @default.
• W2952264931 magId "2952264931" @default.
• W2952264931 workType "article" @default.